Source item
Open original source ↗While the market’s initial response to the appointment of @VPrasadMDMPH to head the CBER was negative, @ARKInvest believes that he will add even more credibility to the @US_FDA’s innovation mindset. The multiomics space is the most inefficiently priced part of the market.
Quoted context
These are the quoted author’s words.
1/ Vinay Prasad at CBER isn't a step back—it's a recalibration. Don't mistake scientific rigor for anti-innovation. He'll press for therapies that work, not just sound good. No more $3M price tags for marginal gains. The goal? Innovation that actually helps patients—not just shareholders. Let me explain
Ovid_ARK ↗